Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab + nedaplatin + docetaxel neoadjuvant therapy for resectable head and neck squamous cell carcinoma
ChiCTR2100044622Phase 2Recruiting
- Sponsor
- Cancer Hospital of Guangxi Medical University
- Start
- Mar 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab, nedaplatin and docetaxel in head and neck squamous cell carcinoma (HNSCC), sponsored by Cancer Hospital of Guangxi Medical University. Primary endpoint: pathologic complete response. Started Mar 2021; status: recruiting.
02
Drugs
toripalimabnedaplatindocetaxel
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2100044622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044622.